Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01 plus Tislelizumab in PD-(L)1-refractory Classical Hodgkin Lymphoma
NCT06465446Phase 3Not yet recruiting
- Sponsor
- ImmuneOnco
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 3 trial of timdarpacept in classical Hodgkin lymphoma (cHL), sponsored by ImmuneOnco. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
timdarpacept
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06465446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465446.